Navigation Links
Supportive tissue in tumors hinders, rather than helps, pancreatic cancer
Date:5/22/2014

HOUSTON Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cancer Cell.

"This supportive tissue that's abundant in pancreatic cancer tumors is not a traitor as we thought but rather an ally that is fighting to the end. It's a losing battle with cancer cells, but progression is much faster without their constant resistance," said study senior author Raghu Kalluri, Ph.D., M.D., chair of Cancer Biology. "It's like having a car with weak yet functioning brakes vs. having one with no brakes."

The team's findings point to a potential new avenue for guiding treatment, including immunotherapy, and offer an explanation for the failure of a promising combination drug approach in clinical trials.

"Cancer is one form of tissue injury. When our defense system detects damaged cells it sends soldiers to contain and repair the damage," Kalluri said. "When it cannot remove the damaged cells and repair the injured area, our defensive fibrotic response tries to put a boundary around it, to contain it and prevent it from spreading."

Pancreatic cancer is resistant to treatment and only about 7 percent of patients survive for five years. An estimated 46,420 new U.S. cases will be diagnosed in 2014 and 39,590 people will die of the disease.

Study results consistent with failed clinical trial

Kalluri and colleagues used genetically engineered mouse models that allowed depletion of tissue-repair cells called myofibroblasts in pancreatic cancer. Myofibroblasts compose a major portion of supportive tissue called stroma and also produce collagen, which serves as a scaffold for wound-healing and tissue regeneration. Up to 90 percent of a pancreatic tumor can consist of fibrotic support tissue.

When the scientists depleted myofibroblast production in mice with either early or later-stage pancreatic ductal adenocarcinoma their tumors became much more invasive, aggressive and lethal.

"We did these experiments thinking that we would show the importance of myofibroblasts and fibrosis in pancreas cancer progression, but the results went completely against that hypothesis," Kalluri said.

Since myofibroblasts and collagen are thought to block chemotherapy, the team treated their myofibroblast-depleted mice with gemcitabine, the standard treatment for pancreas cancer. The drug did not have any effect on the disease course or improve survival.

These results track those of a major clinical trial that combined a myofibroblast-depleting drug called a hedgehog inhibitor with gemcitabine to treat pancreatic cancer patients. The trial was stopped in 2012 when an interim analysis showed the patients taking the combination had faster disease progression than the control group that took only gemcitabine, a surprising result.

"This paradigm-shifting study identifies the reason why the hedgehog-inhibitor trials failed," said co-author Anirban Maitra, M.D., professor of Pathology and scientific director of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research.

All solid tumors include some degree of fibrosis, Maitra said, but not as much as pancreas cancer.

The teams analysis of pancreatic tumors from 53 patients showed low levels of tumor myofibroblasts are associated with decreased survival.

Study findings are consistent with pathologic evidence that tumors with more fibrotic tissue more closely resemble normal pancreas tissue, indicating a better prognosis for patients, even though lab experiments indicated those tumors should be more aggressive, Maitra said.

"These findings also are likely to account for rather modest results in a phase I clinical trial of immunotherapy alone for pancreatic cancer," Maitra said. "But it's not just a negative study, because it suggests what might work for these patients."

And what might work hinges on immune checkpoint blockade.

The immune system connection

To understand the cause of the swift progression, the team conducted gene expression profiling and RNA sequence analysis comparing control tumors to myofibroblast-depleted tumors.

Genes associated with tumor immunity were suppressed and fewer T cells and B cells infiltrated the myofibroblast-depleted tumors. The proportion of regulatory T cells, which suppress immune response, increased. They found greater expression of the immune checkpoint CTLA-4, which shuts down immune response.

The researchers then set up a new experiment using ipilimumab, a drug developed by co-author Jim Allison, Ph.D., chair of Immunology, that blocks CTLA-4, freeing T cells to attack tumors.

Mice with depleted myofibroblasts who were treated with ipilimumab to stifle CTLA-4 had an average survival increase of 60% compared to untreated control mice and those with either depleted myofibroblasts or treated with ipilimumab alone.

These findings suggest that ipilimumab might work for patients with low levels of fibrosis in their tumors, Kalluri noted. Combining ipilimumab with a hedgehog inhibitor is likely to work better for those with high-fibrosis. The Kalluri laboratory is exploring these issues.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. International breast health global summit will focus on supportive care and quality of life
2. Supportive Spouse May Extend Cancer Survival
3. Churchview Supportive Living to Host Music Therapy Informational Program
4. Supportive role models, coping lead to better health in poor teens
5. Churchview Supportive Living to Host African American History Heritage Bowl
6. John Evans Supportive Living to Host Annual Carnival
7. John Evans Supportive Living Community to Host Flu Shot Clinic
8. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
9. Mechanical tissue resuscitation technology shows promise
10. Computing the best high-resolution 3-D tissue images
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The ... how this current generation fits into Bible Prophecy. Yisrayl says this generation, known as ... to this conclusion, showing how the details line up exactly with Bible Prophecy – ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... ... and pharmaceutical organizations to build intelligent, connected applications, was named the best Sales ... , The winner announcement was made today by the Software & Information ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health ... annual Analyst Day in New York City on Thursday, December 15, 2016, ... Health leadership team will provide an in-depth review of ... shareholder value. The company will also discuss 2017 earnings ... video webcast of the event will be broadcast simultaneously ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- Around the corners of world, cancer has infused ... present over earth. Cancer has become one of those ... time this is because of the increasing incidence rates ... steady increase in global cancer incidence with its associated ... of treatment, there is increasing interest in this stringent ...
Breaking Medicine Technology: